At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
EB-001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study to Evaluate Safety and Efficacy of EB-001 Injections in Facial Scar Reduction After Undergoing Mohs Surgery
In Brief
A Phase 2 clinical trial evaluating EB-001 and 0.9% Sodium Chloride Injection for Mohs Surgery. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of EB-001 in improving wound healing and reducing scar formation in patients undergoing Mohs surgery for skin lesions in the forehead area following a single treatment of EB-001 when injected into the muscles underlying the incision area.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMohs Surgery
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartFeb 2018
Primary CompletionJul 2018
Study CompletionOct 2018
TodayJul 2026
First PostedNov 20, 2017
Enrollment StartFeb 6, 2018
Primary CompletionJul 31, 2018
Study CompletionOct 8, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.6 years ago
Interventions
EB-001drug
Injection of EB-001 into area of scarring (forehead)
0.9% Sodium Chloride Injectiondrug
Injection of Saline into area of scarring (forehead)